Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies?

Davide G Ribaldone1, Sharmila Fagoonee, Ingrid Hickman

  • 1Unit of Gastroenterology, Molinette Hospital, Turin, Italy - rinaldo_pellican@hotmail.com.

Minerva Cardioangiologica
|September 8, 2016
PubMed

Insights

Ischemic heart disease (IHD) is a leading cause of death. This review explores the potential link between IHD and Helicobacter pylori (H. pylori) infection, analyzing experimental data for biological plausibility beyond traditional risk factors.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Epidemiology

Background:

  • Ischemic heart disease (IHD) remains a primary cause of mortality and disability globally.
  • Traditional cardiovascular risk factors do not account for all IHD cases, necessitating research into novel etiologic factors.
  • Chronic infections, such as Helicobacter pylori (H. pylori), are being investigated for their potential role in IHD pathogenesis.

Purpose of the Study:

  • To critically analyze existing experimental data regarding the association between H. pylori infection and IHD.
  • To evaluate the biological plausibility of H. pylori as a contributing factor to IHD.
  • To guide future clinical research by assessing the consistency of experimental findings.

Main Methods:

  • Systematic review and critical analysis of experimental studies.
  • Evaluation of laboratory and mechanistic data linking H. pylori to cardiovascular pathways.
  • Assessment of geographical and design variations in epidemiological studies.

Main Results:

  • Conflicting results from epidemiological studies highlight the need for biological plausibility assessment.
  • Experimental data provides insights into potential mechanisms connecting H. pylori to cardiovascular disease.
  • Consistency in biological plausibility may offer a clearer understanding than epidemiological data alone.

Conclusions:

  • Experimental evidence is crucial for understanding the potential role of H. pylori in IHD.
  • Further investigation into the biological mechanisms is warranted.
  • Findings may inform the design of future clinical trials investigating H. pylori and IHD.

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
746
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.4K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
985
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.8K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.5K